ANI Pharmaceuticals (NASDAQ:ANIP) Releases FY 2025 Earnings Guidance

ANI Pharmaceuticals (NASDAQ:ANIP) issued an update on its FY 2025 earnings guidance on Friday morning. The company provided earnings per share guidance of 7.370-7.640 for the period, compared to the consensus earnings per share estimate of 6.730. The company issued revenue guidance of $854.0 million-$873.0 million, compared to the consensus revenue estimate of $847.1 million.

ANI Pharmaceuticals Stock Up 0.2%

ANI Pharmaceuticals stock opened at $90.43 on Friday. ANI Pharmaceuticals has a twelve month low of $52.50 and a twelve month high of $99.50. The company has a debt-to-equity ratio of 1.39, a quick ratio of 1.96 and a current ratio of 2.54. The firm has a market cap of $1.96 billion, a PE ratio of -117.44 and a beta of 0.54. The firm’s 50 day moving average price is $93.58 and its two-hundred day moving average price is $77.60.

ANI Pharmaceuticals (NASDAQ:ANIP) last issued its earnings results on Friday, November 7th. The specialty pharmaceutical company reported $2.04 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.74 by $0.30. The company had revenue of $227.81 million during the quarter, compared to analyst estimates of $211.92 million. ANI Pharmaceuticals had a negative net margin of 1.37% and a positive return on equity of 25.03%. The company’s revenue for the quarter was up 53.6% on a year-over-year basis. During the same quarter last year, the business posted $1.34 EPS. ANI Pharmaceuticals has set its FY 2025 guidance at 7.370-7.640 EPS. On average, research analysts predict that ANI Pharmaceuticals will post 3.86 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of analysts have issued reports on the stock. Zacks Research upgraded shares of ANI Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Thursday, August 21st. HC Wainwright lifted their price target on shares of ANI Pharmaceuticals from $93.00 to $121.00 and gave the company a “buy” rating in a research report on Wednesday, September 17th. JPMorgan Chase & Co. boosted their price objective on shares of ANI Pharmaceuticals from $95.00 to $115.00 and gave the stock an “overweight” rating in a research note on Wednesday, September 24th. Wall Street Zen raised shares of ANI Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Saturday, August 16th. Finally, Truist Financial lifted their target price on shares of ANI Pharmaceuticals from $77.00 to $90.00 and gave the stock a “hold” rating in a report on Thursday, October 9th. Two investment analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating and two have given a Hold rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus target price of $99.14.

Insider Buying and Selling at ANI Pharmaceuticals

In related news, VP Meredith Cook sold 400 shares of the business’s stock in a transaction dated Monday, October 13th. The stock was sold at an average price of $90.09, for a total transaction of $36,036.00. Following the transaction, the vice president directly owned 75,674 shares in the company, valued at $6,817,470.66. The trade was a 0.53% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Matthew J. Leonard sold 2,528 shares of ANI Pharmaceuticals stock in a transaction that occurred on Monday, August 25th. The stock was sold at an average price of $90.62, for a total value of $229,087.36. Following the sale, the director directly owned 6,864 shares in the company, valued at $622,015.68. The trade was a 26.92% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 413,830 shares of company stock valued at $36,505,378 over the last quarter. Company insiders own 11.10% of the company’s stock.

Institutional Investors Weigh In On ANI Pharmaceuticals

Several institutional investors and hedge funds have recently bought and sold shares of the business. CANADA LIFE ASSURANCE Co lifted its holdings in shares of ANI Pharmaceuticals by 1.0% during the 2nd quarter. CANADA LIFE ASSURANCE Co now owns 19,408 shares of the specialty pharmaceutical company’s stock worth $1,267,000 after acquiring an additional 198 shares during the period. Thrivent Financial for Lutherans raised its position in ANI Pharmaceuticals by 2.6% in the second quarter. Thrivent Financial for Lutherans now owns 12,511 shares of the specialty pharmaceutical company’s stock worth $816,000 after purchasing an additional 321 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its stake in ANI Pharmaceuticals by 0.9% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 48,322 shares of the specialty pharmaceutical company’s stock worth $3,235,000 after purchasing an additional 423 shares during the period. Advisors Asset Management Inc. acquired a new stake in ANI Pharmaceuticals during the first quarter valued at approximately $28,000. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in shares of ANI Pharmaceuticals by 4.5% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 10,993 shares of the specialty pharmaceutical company’s stock valued at $736,000 after purchasing an additional 470 shares during the period. Institutional investors own 76.05% of the company’s stock.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.